Effects of amantadine on circulating neurotransmitters in healthy subjects by unknown
BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY - ORIGINAL ARTICLE
Effects of amantadine on circulating neurotransmitters
in healthy subjects
Fuad Lechin • Bertha van der Dijs •
Betty Pardey-Maldonado • Jairo E. Rivera •
Scarlet Baez • Marcel E. Lechin
Received: 20 September 2009 / Accepted: 10 January 2010 / Published online: 4 February 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Considering that glutamatergic axons inner-
vate the C1(Ad) medullary nuclei, which are responsible
for the excitation of the peripheral adrenal glands, we
decided to investigate catecholamines (noradrenaline,
adrenaline and dopamine) plus indolamines (plasma
serotonin and platelet serotonin) at the blood level, before
and after a small oral dose of amantadine, a selective
NMDA antagonist. We found that the drug provoked a
selective enhancement of noradrenaline plus a minimiza-
tion of adrenaline, dopamine, plasma serotonin and
platelet serotonin circulating levels. Significant enhance-
ment of diastolic blood pressure plus reduction of systolic
blood pressure and heart rate paralleled the circulating
parameter changes. The above findings allow us to pos-
tulate that the drug was able to enhance the peripheral
neural sympathetic activity. Minimization of both adrenal
sympathetic and parasympathetic activities was also reg-
istered after the amantadine challenge. The above findings
supported the postulation that this drug should be a
powerful therapeutic tool for treating diseases affected by
adrenal sympathetic hyperactivity.
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Introduction
Adrenal glands secrete adrenaline (Ad) (80%) ? nor-
adrenaline (NA) and dopamine (DA) (20%), approxi-
mately. Sympathetic nerves release NA (80–90%) plus DA.
Both branches of the peripheral sympathetic activity may
act in association or dissociation (Young et al. 1984), in
accordance with the physiological and/or pathophysiolog-
ical circumstances. At the central nervous system level, the
C1(Ad) rostral ventral lateral (RVL) medullary nuclei and
the A5(NA) pontomedullary nucleus are responsible for
these two branches of the peripheral autonomic nervous
system (ANS), respectively (Bazil and Gordon 1993; By-
rum and Guyenet 1987; Guyenet 1984; Li et al. 1992;
Loewy and Haxhiu 1993; Morrison et al. 1991; Strack et al.
1989; Woodruff et al. 1986). Both CNS structures inter-
change inhibitory axons. Adrenaline released from
C1-axons inhibits A5(NA) neurons by acting at alpha-2
post-synaptic receptors, whereas NA released from A5(NA)
axons inhibits the adrenergic nuclei by acting at alpha-2
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inhibitory receptors located at these latter (Li et al. 1992;
Strack et al. 1989; Woodruff et al. 1986).
Amantadine, a glutamate (NMDA) antagonist is con-
sidered as an anti-Parkinson agent because it might atten-
uate the glutamatergic ? acetylcholinergic over the
dopaminergic predominance at the striatal level (Bibbiani
et al. 2005). However, considering that glutamate axons
innervate and excite the RVL medullary nuclei, responsible
for the adrenal sympathetic activity, by acting at NMDA
receptors (Bazil and Gordon 1993; Hand et al. 1997;
Morrison et al. 1991), we decided to asses circulating
neurotransmitters before and after an oral dose of the drug.
With respect to this, we should inform that we have mea-
sured those parameters in some 20,000 normal and dis-
eased subjects. Noradrenaline (NA), adrenaline (Ad),
dopamine (DA), platelet serotonin (p5-HT), plasma sero-
tonin (f5-HT) and plasma tryptophan have been assessed
during supine-resting state and after many types of physi-
ological and pharmacological challenges. The above
parameters have been investigated also in a great deal of
psychiatric and somatic diseases during both relapses and
remission periods (Lechin et al. 1996; Lechin and van der
Dijs 2006a, b). Finally, although we have investigated the
effects of amantadine on circulating neurotransmitters
throughout the oral glucose challenge (Lechin et al. 2009),




Levels of plasma noradrenaline (NA), adrenaline (Ad),
dopamine (DA), free-serotonin (f5-HT), tryptophan, and
platelet serotonin (p5-HT) as well as systolic blood pres-
sure, diastolic blood pressure, and heart rate were measured
before (0 min) and after (60, 90 and 120 min) the oral
administration of 100 mg of amantadine in 35 healthy
volunteers. Platelet aggregation was measured before and
after 120 min of the drug administration. We performed
similar measurements 2 weeks before, in the same volun-
teers after administration of placebo. The group of volun-
teers comprised 19 men and 16 women, whose ages ranged
from 26 to 62 years (mean ± SE = 43.5 ± 4.8). Informed
consent was obtained in writing from all volunteers, and
the procedure was approved by the ethical committee of
FUNDAIME. All volunteers were within 10% of ideal
body weight, none had any physical or psychiatric illness.
Exclusion criteria included pregnancy, lactation, smoking,
and alcohol abuse. Volunteers were recumbent during all
procedures. A heparinized venous catheter was inserted
into a forearm vein at least 30 min before beginning the
test. We used cold, plastic syringes to collect blood sam-
ples at the times specified above. Amantadine (100 mg)
was administered orally after the first blood sample (0 min)
was obtained. Blood samples were obtained for measuring
plasma neurotransmitters and platelet aggregation. Blood
for measuring plasma neurotransmitters was transferred to
plastic tubes, each containing 1 ml of an anti-oxidant
solution (20 mg of EDTA plus 10 mg of sodium metab-
isulphite per ml). The tubes were carefully inverted several
times and placed on ice until centrifugation. To obtain
platelet-rich plasma (PRP), the tubes were centrifuged at
600 rpm at 4C for 15 min. Two milliliters of PRP was
stored at -70C until needed for determination of p5-HT
levels. The remaining blood was centrifuged again at
7,000 rpm, and two aliquots of the supernatant, which was
platelet-poor plasma (PPP), were stored at -70C until
needed for determination of catecholamines and f5-HT
levels. Blood samples for platelet aggregation were pro-
cessed immediately. A physician in constant attendance
noted any symptoms reported by the subjects and moni-
tored heart rate and blood pressure.
Analytical assays
Neurochemistry
Plasma catecholamine and serotonin samples were mea-
sured in duplicate, and all determinations were made at the
same time. We used reverse-phase, ion-pair high perfor-
mance liquid chromatography with electrochemical detec-
tion for the detection of monoamines. Optimization of
chromatographic conditions and attainment of adequate
quantification parameters allowed us to maximize sensi-
tivity and reproducibility (Lechin et al. 1998).
Reagents and standards
Noradrenaline, adrenaline, dopamine, serotonin creatinine
sulphate, dihydroxybenzylamine, sodium octyl sulphate,
dibutylamine, acid-washed aluminium oxide, Na2HPO4,
citric acid and EDTA were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Microfilters were purchased from
Whatman GmbH (Germany) through Merck S.A (Caracas,
Venezuela). Acetonitrile and 2-propanol were obtained
from Merck, S.A. (Caracas, Venezuela). Glass-distilled
water was de-ionized and filtered through a Milli-Q reagent
grade water system (Millipore, Bedford, MA, USA). Sol-
vents were filtered through a 0.2-lm Millipore filter and
were vacuum de-aerated. Standard solutions (1 mmo1/l)
were prepared in 0.1 mo1/l perchloric acid and diluted to
the desired concentration.
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Equipment
Liquid chromatography was performed using Waters 515
HPLC pump (Waters Corporation, Milford, MA, USA)
equipped with a Rheodyne valve injector 7125i, which was
fitted with a 50 ll sample loop (Rheodyne; Berodine,
Berkeley, CA, USA). A 15 cm 9 4.6 mm inner diameter
Discovery C18 column packed with octadecylsilane 5 lm
particles was preceded by a column prefilter of 2 lm
porosity, both from Supelco/Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO, USA). The detection system was a
Waters 460 Electrochemical Detector (Waters Corporation,
Milford, MA, USA). The potential of the working electrode
(glassy carbon) was set at ?0.61 V versus the Ag–AgCl
reference electrode for the detection of catecholamines and
0.70 V versus the Ag–AgCl for the detection of indolam-
ines. The chromatograms were registered and quantified
with the Empower software from Waters Corp. The results
were corrected for the volume of EDTA added.
Catecholamines assay
The assay was performed by extraction of the catechola-
mines onto 20 mg of alumina followed by their elution
with 200 ll of 1.0 mol/l HClO4 using Regenerated Cellu-
lose microfilters 0.2 lm pore size (Whatman GmbH). The
instrument was calibrated with standard plasma: after
incubation with acid-washed aluminium oxide, a plasma
pool of free catecholamines was processed similar to
plasma samples, but 20 ll of a standard solution of nor-
adrenaline, adrenaline and dopamine (50, 25 and 25 ng/ml,
respectively) was added to the plasma pool. Both the
standard plasma and the sample plasma were supplemented
with 20 ll of internal standard (100 ng/ml of dihydr-
oxybenzylamine). The mobile phase was KH2PO4 6.8045
g/l, EDTA 0.100 g/l and di-N-butylamine 100 ll/l. Sodium
octyl sulphate was added as ion-pair agent in a concen-
tration of 0.6125 g/l with the pH adjusted to 5.6. The
sensitivity of this method for noradrenaline, adrenaline and
dopamine was 6.4, 5.8 and 2.0 pg/ml, respectively. The
intra-assay coefficients of variation were 2.8, 4.0 and 4.0%,
respectively. The inter-assay coefficients of variation were
6.7, 4.5 and 4.3%, respectively.
Serotonin assay
After sonication of PRP to disrupt the platelets (Ultrasonic
Liquid Processor, model 385; Heat Systems Ultrasonics
Inc., Farmingdale, NY, USA), both platelet-rich and
platelet-poor plasma were processed in the same way:
200 ll of 3.4 mol/l perchloric acid and 50 ll of 5-hydroxy-
tryptophan solution (114.5 lg/ml) as internal standard
were added to 1 ml of plasma, vortexed and centrifuged at
10,000 rpm for 15 min at 4C. The supernatant was filtered
through a 0.22 lm membrane (Millipore) and 10 ll was
injected into the column. Calibration runs were generated
by spiking blank platelet-poor plasma with 50 ll of a
solution containing 5-HT (10 lg/ml) and 50 ll of
5-hydroxy-tryptophan (114.5 lg/ml). This standard plasma
was processed in the same manner as the samples. The
mobile phase was citric acid 3.8424 g/l, sodium acetate
4.1015 g/l, EDTA 0.100 g/l, di-N-butylamine 100 ll/l and
30 ml/l of 2-propanol. Sodium octyl sulphate was added as
ion-pair agent in a concentration of 4.25 mg/l with a pH of
5.0. The sensitivity of the method for serotonin was 0.1 ng/
ml. The intra-assay coefficients of variation for p5-HT and
f5-HT were 6.2 and 8.7%, respectively.
Platelet aggregation
Blood was collected with citrate–phosphate dextrose (1:9
v/v) as the anticoagulant. Blood was subsequently centri-
fuged at 120g for 10 min to prepare PRP. Aggregation
studies were carried out according to Born’s (1962)
method, and aggregation was induced by ADP and colla-
gen at final concentrations of 4 lmol/l and 4 lg/ml,
respectively. Maximal aggregation, expressed as the per-
centage of maximal light transmission, was measured.
Statistical methods
Results are presented as the mean ± SEM. Statistical sig-
nificance was set at P \ 0.05. Multivariate ANOVA with
repeated measurements and correlation coefficients
(exploratory factor analysis) were used. Dbase Stats (TM)
by Ashton Tate and Statview SE ? Graphics by Abacus
were used for statistical analyses.
Results
Significant increases of noradrenaline plus decreases of
adrenaline and dopamine plasma levels were registered at
all post-amantadine periods. Maximal effects for these
catecholamines occurred at 90 and 120 min periods
(Fig. 1). Hence, significant increases in noradrenaline/
adrenaline and noradrenaline/dopamine ratios were also
registered at these periods (Fig. 2).
Both f5-HT and p5-HT parameters showed significant
decreases throughout the amantadine but not the placebo
test. Tryptophan changes were not observed throughout the
placebo or the amantadine tests (Fig. 3).
No significant increases of platelet aggregation were
registered after the amantadine challenge (120 min).
Significant and sustained systolic blood pressure and
heart rate decreases were registered throughout the
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amantadine but not the placebo test. Conversely, significant
and sustained diastolic blood pressure rises were observed
after the amantadine challenge but not after the placebo
administration (Fig. 4). Hence, amantadine minimized
systolic blood pressure plus heart rate and enhanced dia-
stolic blood pressure.
Significant and progressive negative correlations were
found between NA and DA and between NA/Ad ratio and
DA throughout the amantadine test. Positive correlations
were found between NA/Ad ratio and diastolic blood
pressure. Adrenaline versus f5-HT showed significant
positive correlation values at post-drug periods (see
Table 1).
Discussion
We demonstrated in the present study that a small dose of
oral amantadine triggered abrupt and significant reduction
of the adrenaline plasma levels which contrasted the sig-
nificant rises of plasma noradrenaline. In addition, signifi-
cant reductions of dopamine plasma values were also
registered. Furthermore, maximal decreases of both p5-HT
and f5-HT were produced throughout the test.
The enhancement of both the NA/AD plus NA/DA ratios
registered after the amantadine challenge is consistent with
the postulation of the minimization of the adrenal sympa-
thetic activity plus the enhancement of the neural sympa-
thetic activity. With respect to this, it should be remembered
that the A5(NA) pontomedullary nucleus, which inter-
changes inhibitory axons with the C1(Ad) RVL medullary
nuclei (Byrum and Guyenet 1987; Guyenet 1984; Morrison
et al. 1991), is responsible for the neural sympathetic
activity (Morrison et al. 1991; Woodruff et al. 1986),
whereas the latter nuclei excite adrenal glands secretion of
catecholamines (Ad ? DA and NA) (Strack et al. 1989).
These medullary nuclei are crowded by excitatory gluta-
matergic (NMDA) receptors (Caringi et al. 1998; Drye et al.
1990; Elenkov et al., 2000; Li et al. 1992; Loewy and
Haxhiu 1993; Maiorov et al. 1999; Strack et al. 1989).
The significant and abrupt fall of serotonin plasma levels
(f5-HT) registered in this study should be attributed to the
minimization of circulating adrenaline, triggered by the
drug. Thus, 5-HT is retained into the platelet store. This
issue is consistent with the significant positive correlations
between adrenaline versus f5-HT values, registered
throughout the post-amantadine periods. This factor should
Fig. 1 Noradrenaline, adrenaline and dopamine plasma levels before
and after placebo and amantadine test performed 2 weeks apart in 35
healthy volunteers (19 men and 16 women). Results are expressed as
mean ? SE as the error bars. *P \ 0.05, **P \ 0.01, ***P \ 0.001
(amantadine versus placebo)
Fig. 2 Amantadine induced a significant rises of the noradrenaline/
adrenaline ratio as well as on the noradrenaline/dopamine ratio at the
90 and 120 min periods while a light significant fall was registered at
90 min period on the adrenaline/dopamine ratio after placebo and
amantadine tests were performed 2 weeks apart in 35 healthy
volunteers (19 men and 16 women). Results are expressed as
mean ? SE as the error bars. *P \ 0.05, **P \ 0.01, ***P \ 0.001
(amantadine versus placebo)
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be added to the reduction of parasympathetic activity
triggered by the overwhelming neural sympathetic pre-
dominance registered after the amantadine challenge. With
respect to this, it should be known that parasympathetic
nerves excite enterochromaffin cells which release seroto-
nin to the blood stream (Schwo¨rer et al. 1987; Tobe et al.
1976). In addition, circulating acetylcholine interferes with
the uptake of 5-HT by platelets (Rausch et al. 1985).
Furthermore, plasma serotonin excites the medullary area
postrema (it is located outside of the blood brain barrier)
(Reynolds et al. 1989; Wilson and Bonham 1994). This
nucleus sends excitatory axons to the C1(Ad) nuclei
(Gauthier and Reader 1982; Urbanski and Sapru 1988),
thus minimization of this mechanism is responsible for the
inhibition of the adrenal sympathetic activity, normally
registered during postprandial periods (Lechin 2000;
Lechin et al. 1993; 2009). Hence, amantadine would also
be able to annul adrenal sympathetic activity throughout
the minimization of the area postrema—C1(Ad) axis which
depends on the serotonin release by enterochromaffin cells
during postprandial parasympathetic period. With respect
to the latter, it has been demonstrated that the C1(Ad)
nuclei receive excitatory axons from the area postrema
(Schwo¨rer et al. 1987; Tobe et al. 1976; Urbanski and
Sapru 1988).
Fig. 3 Plasma serotonin, platelet serotonin and plasma tryptophan
circulating levels before and after placebo and amantadine test
performed 2 weeks apart in 35 healthy volunteers (19 men and 16
women). Results are expressed as mean ? SE as the error bars.
*P \ 0.05, **P \ 0.01, ***P \ 0.001 (amantadine versus placebo)
Fig. 4 Cardiovascular parameters registered before and after placebo
and amantadine test performed 2 weeks apart in 35 healthy volunteers
(19 men and 16 women). Results are expressed as mean ? SE as the
error bars. *P \ 0.05, **P \ 0.01, ***P \ 0.001 (amantadine versus
placebo)
Table 1 Significant correlations (r) after oral administration of
amantadine 100 mg or placebo in 35 healthy volunteers (19 men and
16 women
60 min 90 min 120 min
NA versus DA
Amantadine -0.43** -0.67** -0.81***
Placebo n.s. n.s. n.s.
NA/Ad versus DA
Amantadine -0.61** -0.77*** -0.89***
Placebo n.s. n.s. n.s.
NA/Ad versus DBP
Amantadine 0.54* 0.65** 0.69**
Placebo n.s. n.s. n.s.
Ad versus f5-HT
Amantadine 0.58** 0.69** 0.77***
Placebo n.s n.s n.s
NA noradrenaline, DA dopamine, Ad adrenaline, DBP diastolic blood
pressure, n.s. non-significant
* P \ 0.05, **P \ 0.01, ***P \ 0.001
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Summarizing, it should be concluded that amantadine
annulled both parasympathetic and adrenal sympathetic
activities and favored neural sympathetic predominance. In
addition, the neural sympathetic overactivity provoked by
amantadine interferes with the parasympathetic drive
responsible for the release of intestinal serotonin which
redounded in the reduction of both p5-HT and f5-HT cir-
culating levels. With respect to this, we have quoted
exhaustive evidence showing the existence of two types of
opposite ANS profiles which underlie most diseases: (1)
adrenal sympathetic and (2) neural sympathetic (Lechin
and van der Dijs 2008, 2009a, b).
According to all the above, we concluded that the
administration of an oral dose of amantadine was able to
provoke the enhancement of the neural sympathetic branch
which minimized both adrenal sympathetic and parasym-
pathetic activities, as reflected by the peripheral autonomic
system parameters plus the circulating neurotransmitters
profile. The above findings allow the understanding of
several therapeutic effects triggered by this drug.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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medium, provided the original author(s) and source are credited.
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